Commentary on “Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy.”

Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes.

Source: Urologic Oncology: Seminars and Original Investigations - June 4, 2018 Category: Urology & Nephrology Authors: DE Thomas, HZ Kaimakliotis, KR Rice, JA Pereira, P Johnston, ML Moore, A Reed, DM Cregar, C Franklin, RL Loman, MO Koch, R Bihrle, RS Foster, TA Masterson, TA Gardner, CP Sundaram, CR Powell, SDW Beck, DJ Grignon, L Cheng, C Albany, NM. Hahn Tags: Urologic Oncology Survey Source Type: research